<h1>Pharma Giant Achieves Double-Digit Growth in Revenue, Profit, and R&D Investment for Fiscal Year 2025</h1> Pharmaceutical company reported strong financial performance in fiscal year 2025. Revenue increased by 19% to Rs. 2,32,415 million, with net profit rising 23% to Rs. 47,451 million. EBITDA grew 31% to Rs. 70,585 million, with margin improving to 30.4%. The company maintained a negative net debt position of Rs. 48,836 million and invested Rs. 18,555 million in research and development. Management expressed satisfaction with business growth and strategic progress.